Table 2.
Pharmacokinetic parameters for antibody 1B7 formulations.
| Group | N |
Injection volume (μl) |
Dose (mg/kg) |
Cmax/dose (μg/ml)/ (mg/kg) |
AUC0-∞/ dose (μg·hr/ml)/(mg/ kg) |
tmax (hours) | t1/2,α (hours) | t1/2,β (hours) |
Relative
neutralization activity |
|---|---|---|---|---|---|---|---|---|---|
| 1: IV solution * | 6 | 100 | 5.6 | 25.5 ± 3.8 | 3582 ± 990 | 15.1 ± 0.7 | 45.7 ± 22.8 | 227.1 ± 24.9 | 2.3 ± 1.7 |
| 2: SQ solution * | 4 | 100 | 5.6 | 18.8 ± 4.4 | 2699 ± 583 | 18.9 ± 3.1 | 43.4 ± 17.3 | 210.0 ± 17.4 | 1.0 ± 1.8 |
| 3: SQ diluted dispersion |
5 | 100 | 4.6 | 9.1 ± 3.2 | 1790 ± 630 | 28.8 ± 12.0 | 54 ± 21 # | 219 ± 25 | 0.4 ± 0.2 |
| 4: SQ dispersion, standard dose |
5 | 1 | 7.3 | 7.3 ± 1.3 | 1345 ± 467 | 20.1 ± 3.2 | 49 ± 29 # | 180± 16 | 0.5 ± 0.2 |
| 5: SQ dispersion, high dose |
6 | 100 | 51.6 | 7.6 ± 2.6 | 1919 ± 566 | 20.2 ± 5.2 | 51 ± 23 # | 250± 24 | 2.1 ± 1.0 |
*
Data previously reported in (18)
#
t1/2,α determined from 2 points for some mice